Portal de Periódicos da CAPES

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

2008; Elsevier BV; Volume: 113; Issue: 14 Linguagem: Inglês

10.1182/blood-2008-07-167379

1528-0020

Benedetto Bruno, Marcello Rotta, Francesca Patriarca, Daniele Mattei, Bernardino Allione, Fabrizio Carnevale‐Schianca, Roberto Sorasio, Alessandro Rambaldi, Marco Casini, Matteo Parma, P Bavaro, Francesco Onida, Alessandro Busca, Luca Castagna, E. Benedetti, Anna Paola Iori, Luisa Giaccone, Antonio Palumbo, Paolo Corradini, Renato Fanin, David G. Maloney, Rainer Storb, Ileana Baldi, Umberto Ricardi, Mario Boccadoro,

Cancer therapeutics and mechanisms

Abstract Despite recent advances, allografting remains the only potential cure for myeloma. From July 1999 to June 2005, 100 newly diagnosed patients younger than 65 years were enrolled in a prospective multicenter study. First-line treatment included vincristin, adriamycin, and dexamethasone (VAD)–based induction chemotherapy, a cytoreductive autograft (melphalan 200 mg/m2) followed by a single dose of nonmyeloablative total body irradiation and allografting from an human leukocyte antigen (HLA)–identical sibling. Primary end points were the overall survival (OS) and event-free survival (EFS) from diagnosis. After a median follow-up of 5 years, OS was not reached, and EFS was 37 months. Incidences of acute and chronic graft-versus-host disease (GVHD) were 38% and 50%, respectively. Complete remission (CR) was achieved in 53% of patients. Profound cytoreduction (CR or very good partial remission) before allografting was associated with achievement of posttransplantation CR (hazard ratio [HR] 2.20, P = .03) and longer EFS (HR 0.33, P < .01). Conversely, development of chronic GVHD was not correlated with CR or response duration. This tandem transplantation approach allows prolonged survival and long-term disease control in patients with reduced tumor burden at the time of allografting. We are currently investigating the role of “new drugs” in intensifying pretransplantation cytoreduction and posttransplantation graft-versus-myeloma effects to further improve clinical outcomes. (http://ClinicalTrials.gov; NCT-00702247.)